Clinical Trial Detail

NCT ID NCT03104491
Title Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
Recruitment Suspended
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Leland Metheny
Indications

acute lymphocytic leukemia

Therapies

inotuzumab ozogamicin

Age Groups: adult child senior

Additional content available in CKB BOOST